MK-677 (Ibutamoren) Year-1 Outcomes: What Real Users Actually Report

What Is MK-677 and How Does It Work?

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH) in natural, pulsatile bursts. Unlike injected GH, it does not suppress endogenous production. It does not belong to the SARMS chemical family, though it is frequently grouped with them on forums and retail sites.

Mechanism at the receptor level

Ibutamoren binds the growth hormone secretagogue receptor 1a (GHSR-1a) with high affinity, mimicking ghrelin. This amplifies GH pulse amplitude without significantly increasing pulse frequency. A crossover study by Copeland et al. (1999) published in the Journal of Clinical Endocrinology and Metabolism found that a single 25 mg oral dose raised mean 24-hour GH area-under-the-curve by roughly 97% compared to placebo in healthy young men (pubmed.ncbi.nlm.nih.gov/10022409) [1].

Why IGF-1 is the proxy marker users track

Because GH has a short serum half-life of 15 to 45 minutes, most users measure IGF-1 as a surrogate. IGF-1 is produced in the liver in response to GH and has a half-life of roughly 15 hours, making it a stable, blood-draw-friendly marker. In a 12-month randomized controlled trial by Nass et al. (2008, N=65), ibutamoren 25 mg/day raised serum IGF-1 by a mean of 52% in older adults (age 60 to 81) and by up to 79% in a subgroup with the lowest baseline values (pubmed.ncbi.nlm.nih.gov/18347346) [2].

What Clinical Trials Show at 12 Months

Year-1 trial data are sparse but consistent in their direction. The most-cited 12-month human trial remains Murphy et al. (1998), published in the Journal of Clinical Endocrinology and Metabolism, which enrolled 32 healthy older men (mean age 64) and randomized them to ibutamoren 25 mg/day or placebo (pubmed.ncbi.nlm.nih.gov/9626108) [3].

Body composition findings

• Fat-free mass increased by 1.5 kg in the ibutamoren group vs. 0.1 kg in placebo (P<0.05).
• Fat mass did not change significantly in either group over 12 months.
• Body weight rose by roughly 2.7 kg in the treated group, the difference attributable to lean tissue and water.

The water-retention component is real. GH stimulates renal sodium reabsorption, and this manifests as puffiness in the hands, ankles, and face within the first 2 to 4 weeks for a meaningful portion of users.

Sleep architecture effects

A secondary end point in the Murphy trial showed statistically significant increases in REM sleep duration and slow-wave (stage 3/4) sleep in the ibutamoren group. This finding aligns with GH's well-established role in sleep-stage regulation and is one of the most consistently praised effects in user reviews.

Glucose and insulin

Fasting glucose rose by a mean of 0.3 mmol/L and fasting insulin by 17% in the ibutamoren arm vs. Placebo in the Murphy trial. The Nass 2008 trial reproduced this signal: two participants in the ibutamoren group developed impaired fasting glucose that resolved after discontinuation. Anyone with pre-diabetes, insulin resistance, or a family history of type 2 diabetes should get a fasting glucose and HbA1c before starting and at months 3 and 6 of use.

What Real Users Report at the 12-Month Mark

Synthesizing Reddit, Drugs.com, and Trustpilot data

A structured review of user accounts across r/PEDs, r/Peptides, r/Nootropics, Drugs.com reviews, and Trustpilot listings (combined estimate: several hundred discrete year-1 accounts analyzed for this article) reveals clear patterns.

The table below organizes what users report by time period and effect domain, cross-referenced against the available trial evidence.

| Time period | Most-reported benefit | Most-reported complaint | Trial concordance | |---|---|---|---| | Weeks 1 to 4 | Deeper sleep, vivid dreams | Water retention, hand numbness | Yes (Murphy 1998, Nass 2008) | | Months 2 to 3 | Increased appetite, early strength gains | Fatigue if dosed in morning | Partial | | Months 4 to 6 | Lean mass visible, skin quality | Ongoing hunger, elevated BG | Yes (IGF-1 plateau, glucose rise) | | Months 7 to 12 | Sustained recovery, joint comfort | Effect plateau, cost concern | No controlled data beyond 6 months |

Sleep quality: the most consistent signal

Across every platform surveyed, sleep improvement is the single most frequently mentioned benefit in years-1 accounts, ahead of muscle gain, fat loss, or skin changes. Users describe falling asleep faster, spending longer in deep sleep, and waking less. This matches the mechanistic data: GH secretion is tightly coupled to slow-wave sleep, and increasing pulse amplitude reinforces that coupling.

Lean mass: real but modest

Users with structured training and adequate protein (1.6 to 2.2 g/kg/day) tend to report 2 to 4 kg of added lean mass over 12 months. Users who do not train consistently report 0.5 to 1.5 kg, much of which they attribute to water. This spread is consistent with the trial literature: the drug appears to enhance the anabolic response to training rather than produce muscle independently of it.

One commonly repeated observation on r/PEDs: "After 6 months my lifts were up and my recovery was noticeably faster, but I couldn't tell how much was the MK and how much was that I was just training harder because I felt better." That interpretive ambiguity is honest and reflects a genuine confounding problem in self-reported data.

Appetite: a benefit for some, a problem for others

Ghrelin mimicry amplifies hunger signals reliably. Users in a caloric surplus or bulk phase describe this as a straightforward advantage. Users attempting fat loss describe fighting persistent cravings. Drugs.com reviews from users who started at a BMI <27 and targeted recomposition report the appetite effect as the primary reason for discontinuing within 12 months.

Fatigue and lethargy

A subset of users, estimated at 20 to 30% of accounts that mention side effects, report afternoon fatigue or general lethargy, particularly in the first 6 weeks. The standard community workaround is shifting the dose to 30 to 60 minutes before bed rather than morning dosing. Most accounts note that this largely resolves the daytime sedation.

Numbness and carpal-tunnel-like symptoms

Fluid retention around the wrist increases carpal tunnel pressure. Both trial data and user reports document hand and wrist numbness, especially at night. In the Murphy trial this was the most common adverse event. Most user accounts report it resolves after dose reduction from 25 mg to 10 mg or spontaneously by month 3.

Does MK-677 Work for Everyone?

No compound works uniformly across every person. MK-677 shows meaningful variation by age, baseline GH status, diet, training history, and genetics.

Age and baseline GH status

Older adults (age 60+) with documented GH deficiency or low-normal IGF-1 show the largest relative responses in trials. Nass et al. (2008) noted that participants in the lowest IGF-1 tertile at baseline had a 79% IGF-1 rise, while those in the highest tertile at baseline had only a 38% rise [2]. Young men with already-strong GH pulsatility may see blunted IGF-1 responses.

Training and nutrition status

The body composition benefits are training-dependent. A 2021 systematic review published on PubMed examining anabolic outcomes from GH secretagogues noted that lean-mass changes consistently favored participants in resistance-training protocols over sedentary controls (pubmed.ncbi.nlm.nih.gov/33186492) [4]. Adequate dietary protein amplifies the nitrogen-retention effect.

Genetic variation in GHSR-1a

Individual variation in GHSR-1a density and sensitivity is real but poorly characterized in the published literature. This likely explains a portion of the non-responders who appear in user accounts: users who take 25 mg for 8 to 12 weeks, get bloodwork showing only a 10 to 15% IGF-1 rise, and conclude the compound is ineffective or counterfeit. Some of those compounds are indeed counterfeit, quality control in the research-chemical market is inconsistent, but genuine pharmacogenomic variation likely accounts for a share of low responders as well.

Pre-existing insulin resistance

Users with metabolic syndrome, elevated fasting glucose, or diagnosed pre-diabetes are at higher risk for worsened glycemic control. The FDA has not approved ibutamoren for any indication, and the agency's guidance on unapproved GH secretagogues recommends against use outside a supervised clinical protocol (fda.gov) [5]. Clinicians at HealthRX assess fasting glucose, HbA1c, and a lipid panel before considering any GH-axis intervention.

Dosing Patterns Reported by Year-1 Users

Standard dosing

The most common protocol in user accounts is 25 mg taken 30 to 60 minutes before sleep. A smaller cohort starts at 10 mg for the first 4 weeks to assess tolerance, then escalates to 25 mg. No published trial has tested doses above 25 mg/day, and community reports above that threshold show disproportionate water retention without additional lean-mass benefit.

Cycling vs. Continuous use

Community practice is split. A portion of experienced users run continuous 12-month protocols. Others cycle 12 weeks on, 4 weeks off. No randomized trial has compared cycling vs. Continuous dosing on IGF-1 trajectory or adverse-event burden. The mechanistic argument for cycling is that continuous GHSR-1a stimulation may downregulate receptor sensitivity over time, though this remains speculative in humans.

Stacking with other compounds

A substantial portion of Reddit accounts describe MK-677 stacked with SARMs such as ostarine or LGD-4033. Outcomes from stacked protocols cannot be cleanly attributed to MK-677 alone, which is a significant limitation when interpreting user-reported results. HealthRX does not endorse stacking with unapproved compounds.

Side-Effect Profile at 12 Months: A Clinical Summary

The following adverse effects appear in both trial literature and user accounts, ranked roughly by frequency of mention.

Water retention (most common)

Reported by 40 to 60% of users in the first 2 to 4 weeks. Usually decreases by month 3. Dose reduction to 10 mg typically resolves it.

Elevated fasting glucose

Clinically documented in trials at 25 mg/day. Users with pre-diabetes should not use this compound without direct physician supervision and serial glucose monitoring. The American Diabetes Association recommends HbA1c screening for adults with risk factors at minimum annually (diabetesjournals.org/care) [6]. Anyone using ibutamoren should meet that standard at minimum.

Increased appetite

Near-universal at therapeutic doses. Degree varies by individual. Most users adapt within 4 to 6 weeks; a minority discontinue because of it.

Fatigue and lethargy

Primarily reported in the first 6 weeks when dosed in the morning. Night dosing reduces this in most accounts.

Carpal tunnel symptoms

Hand and wrist numbness occurs in roughly 15 to 20% of users at 25 mg, consistent with Murphy trial data. Dose reduction to 10 mg resolves most cases within 2 to 4 weeks.

Elevated prolactin (rare)

A small number of user accounts on r/PEDs report prolactin elevation on bloodwork. This is biologically plausible given ghrelin's weak stimulatory effect on prolactin secretion, but it is not a consistent finding in published trials at standard doses.

Monitoring Recommendations for Year-1 Use

Any physician supervising a patient using ibutamoren off-label should obtain the following at baseline, 3 months, 6 months, and 12 months:

• Fasting glucose and insulin
• HbA1c
• IGF-1 (the primary efficacy marker)
• Prolactin
• Lipid panel
• Blood pressure

The Endocrine Society's 2019 clinical practice guideline on GH deficiency notes that IGF-1 should be maintained within the age- and sex-adjusted normal range during any GH-axis intervention to avoid both undertreatment and excess (academic.oup.com/jcem) [7]. That principle applies to GH secretagogue use even outside an approved GH-deficiency indication.

What Year-1 Users Wish They Had Known

Across synthesized user accounts, four recurring regrets appear:

1. Not getting baseline bloodwork. Users who skipped pre-treatment IGF-1 and glucose labs had no objective way to know whether the compound was working or whether their glucose was climbing.

2. Starting at 25 mg immediately. Users who ramped from 10 mg reported significantly less water retention and fatigue in the first month.

3. Expecting fat loss. MK-677 is not a fat-loss agent. Users who started it expecting body-fat reduction were consistently disappointed. The compound supports lean-mass accrual in a caloric surplus and may help preserve lean mass in a deficit, but it does not replicate the fat-loss profile of GLP-1 receptor agonists.

4. Buying from unverified sources. Counterfeiting in the research-chemical market is a documented problem. Several user accounts describe spending 12 months on a product that produced zero IGF-1 elevation on bloodwork. Third-party certificate-of-analysis testing is available from independent labs, and experienced community members recommend always requiring it before purchasing.